Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVI 816

Next Previous
X
Search
Drug Profile

MVI 816

Alternative Names: PAP Vaccine - Madison Vaccines; pTVG-HP; pTVG-HP Plasmid DNA Vaccine

Latest Information Update: 11 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Madison Vaccines
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 27 Jul 2023 Madison Vaccines and University of Wisconsin completes a phase I/II trial in Prostrate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal) (NCT02499835)
  • 13 Sep 2022 Bristol-Myers Squibb discontinued phase II trial in Prostate cancer in USA (NCT03600350)
  • 28 Sep 2021 MVI 816 is still in phase II trials for Prostrate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top